Vireo Growth (VREOF) Free Cash Flow (2020 - 2026)
Vireo Growth (VREOF) reported Free Cash Flow of $1.1 million for Q1 2026, up 124.44% on a YoY basis from $490099.0 in Q1 2025, and down 87.49% sequentially from $8.8 million in Q4 2025.
Vireo Growth (VREOF) Free Cash Flow (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Free Cash Flow data on file, last reported at $1.1 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 124.44% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$19.0 million (up 21.89% YoY), and the FY2025 full-year result was -$24.6 million, down 12.23% from the prior year.
- Free Cash Flow slipped to $1.1 million in Q1 2026, from $8.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $8.8 million in Q4 2025 to a low of -$20.5 million in Q3 2025.
- A 5-year average of -$4.4 million and a median of -$4.0 million in 2023 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow sank 597.52% in 2024 and surged 195.96% in 2025, its largest moves.
- Tracing VREOF's Free Cash Flow over 5 years: stood at -$6.7 million in 2022, then surged by 58.59% to -$2.8 million in 2023, then slumped by 228.21% to -$9.2 million in 2024, then surged by 195.96% to $8.8 million in 2025, then tumbled by 87.49% to $1.1 million in 2026.
- Business Quant data shows VREOF's Free Cash Flow at $1.1 million in Q1 2026, $8.8 million in Q4 2025, and -$20.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 1.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.10 Mn |
| Mar 31, 2026 | 1.10 Mn |
| Dec 31, 2025 | 8.79 Mn |
| Dec 31, 2025 | 8.79 Mn |
| Sep 30, 2025 | -20.45 Mn |
| Sep 30, 2025 | -20.45 Mn |
| Jun 30, 2025 | -8.46 Mn |
| Jun 30, 2025 | -8.46 Mn |
| Mar 31, 2025 | -4.50 Mn |
| Mar 31, 2025 | -4.50 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Dec 31, 2024 | -9.16 Mn |
| Sep 30, 2024 | -7.48 Mn |
| Sep 30, 2024 | -7.48 Mn |
| Jun 30, 2024 | -3.20 Mn |
| Jun 30, 2024 | -3.20 Mn |
| Mar 31, 2024 | -2.09 Mn |
| Mar 31, 2024 | -2.09 Mn |
| Dec 31, 2023 | -2.79 Mn |
| Dec 31, 2023 | -2.79 Mn |